FDA Issues CRL for Summit Therapeutics’ Ivonescimab BLA
The FDA issued a Complete Response Letter for Summit Therapeutics’ biologics license application for ivonescimab plus platinum-containing chemotherapy in non-small cell lung cancer.
The FDA issued a Complete Response Letter for Summit Therapeutics’ biologics license application for ivonescimab plus platinum-containing chemotherapy in non-small cell lung cancer.